Three months of romosozumab did not improve hip bone strength, but 12 months did, supporting completion of the full regimen in patients with osteoporosis.
|Slideshows|February 2, 2016
2015 ACR-EULAR Gout Criteria Scoring
In 2015, ACR and EULAR issued classification criteria for gout. The scoring system is summarized here in an easy to use format for physicians and patients.
Advertisement
In 2015, the American College of Rheumatology and the European League Against Rheumatism issued classification criteria for gout. This slideshow summarizes the scoring system in an easy to use format for physicians and patients.
Advertisement
Related to this article
The new 30-mg/5-mL formulation offers an alternative for adults who have difficulty swallowing capsules.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Advertisement
Advertisement